Point72 Asset Management
BBIO icon

Point72 Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Point72 Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
23,600
+19,800
+521% +$1.44M ﹤0.01% 2402
2025
Q4 		$291K Buy
+3,800
New +$249K ﹤0.01% 3488
2025
Q2 		– Sell
-100,000
Closed -$3.46M – 2181
2025
Q1 		$3.46M Buy
+100,000
New +$3.37M 0.01% 1071
2024
Q3 		– Sell
-30,000
Closed -$760K – 1981
2024
Q2 		$760K Buy
+30,000
New +$820K ﹤0.01% 1340
2022
Q1 		– Sell
-30,700
Closed -$512K – 1171
2021
Q4 		$512K Buy
+30,700
New +$1.3M ﹤0.01% 962

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's BBIO Position: Q2 2025 in Review

Point72 Asset Management sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 198,780 shares — an estimated $6.87M sold.

Point72 Asset Management first reported a position in BBIO in Q2 2019 and held it in 6 quarters. The position peaked at $6.87M in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

  • Point72 Asset Management reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
  • Point72 Asset Management sold 198,780 BridgeBio Pharma shares in Q2 2025, an estimated $6.87M.
  • Point72 Asset Management first reported a position in BridgeBio Pharma in Q2 2019 and held it in 6 quarters.
  • Point72 Asset Management's BridgeBio Pharma position peaked at $6.87M in Q1 2025.
  • 359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.